VHCP Management III, LLC
Follow13F filer, CIK 1738053, New York, NY
VHCP Management III, LLC reported $161,989,000 across 17 holdings for the quarter ended 2019-09-30, in a 13F-HR filed 2019-11-13. Its ten largest share positions make up 95.51% of the portfolio.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-19-010838
- Period
- 2019-09-30
- Reported value
- $162M
- Holdings
- 17
- Top 10 weight
- 95.51%
- New
- 3
- Sold out
- 3
Part of the filer group Venrock Healthcare Capital Partners III, L.P.
Nimish ShahKoh Bong Y
Stakes and trades reported after 2019-09-30
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- OKUR ONKURE THERAPEUTICS INC: 13G 2,309,559 shares, 5.7% of the class, 13G filed 2026-11-20, 0001231919-26-001621Timeline
Accepted , ingested - ENTX ENTERA BIO LTD: 13G 8,861,763 shares, 5.1% of the class, 13G filed 2026-10-30, 0001738048-26-000079Timeline
Accepted , ingested - LYCA LYCIA THERAPEUTICS INC: 13G 6,850,237 shares, 11.9% of the class, 13G filed 2026-10-30, 0001738048-26-000077Timeline
Accepted , ingested - FLSC FRAZIER LIFE SCIENCES ACQ-A: 13G 700,000 shares, 9% of the class, 13G filed 2026-10-27, 0001738048-26-000075Timeline
Accepted , ingested - XFOR X4 PHARMACEUTICALS INC: 13G/A 7,644,072 shares, 7.6% of the class, 13G/A filed 2026-11-16, 0001738048-26-000100Timeline
Accepted , ingested - VOR VOR BIOPHARMA INC: 13G/A 6,443,619 shares, 9.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000098Timeline
Accepted , ingested - KRRO KORRO BIO INC: 13G/A 1,474,162 shares, 9.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000096Timeline
Accepted , ingested - JBIO JADE BIOSCIENCES INC: 13G/A 3,858,984 shares, 5.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000094Timeline
Accepted , ingested - HELP HELUS PHARMA INC: 13G/A 2,688,175 shares, 3.5% of the class, 13G/A filed 2026-11-16, 0001738048-26-000092Timeline
Accepted , ingested - CBIO CRESCENT BIOPHARMA INC.: 13G/A 2,228,641 shares, 5.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000090Timeline
Accepted , ingested - ACHV ACHIEVE LIFE SCIENCE INC: 13G/A 5,502,064 shares, 5.2% of the class, 13G/A filed 2026-11-16, 0001738048-26-000088Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| TXGnew | +300,000 | $15.1M |
| MARINUS PHARMACEUTICALS INCadded | +1,257,200 | $1.94M |
| RADIUS HEALTH INCnew | +23,131 | $596K |
| PREVAIL THERAPEUTICS INCnew | +4,408 | $54K |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| ORCHARD THERAPEUTICS PLCexited | -676,252 | -$9.46M |
| TRICIDA INCreduced | -209,398 | -$6.46M |
| KADMON HOLDINGS INCexited | -422,141 | -$870K |
| GEMPHIRE THERAPEUTICS INCexited | -798,066 | -$646K |
| KINIKSA PHARMACEUTICALS LTDreduced | -35,183 | -$299K |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q3 2019
Share positions as resolved from 13F-HR 0000950123-19-010838, largest first. % of portfolio is the value over $161,989,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| MISTMILESTONE PHARMACEUTICALS IN | 2,066,529 | $38.5M | 23.79% | 0 | Timeline | ||
| AXSMAXSOME THERAPEUTICS INC. | 1,611,329 | $32.6M | 20.13% | 0 | Timeline | ||
| RA PHARMACEUTICALS INCRA PHARMACEUTICALS INC | 670,350 | $15.9M | 9.79% | 0 | |||
| TXG10X GENOMICS INC | 300,000 | $15.1M | 9.33% | new | Timeline | ||
| PTGXPROTAGONIST THERAPEUTICS INC | 1,072,348 | $12.9M | 7.95% | 0 | Timeline | ||
| LA JOLLA PHARMACEUTICAL COLA JOLLA PHARMACEUTICAL CO | 1,251,898 | $11M | 6.8% | 0 | |||
| ObsEva SAObsEva SA | 1,159,789 | $9.66M | 5.96% | 0 | |||
| BCRXBIOCRYST PHARMACEUTICALS INC | 2,708,207 | $7.76M | 4.79% | 0 | Timeline | ||
| KALVKALVISTA PHARMACEUTICALS INC | 637,884 | $7.4M | 4.57% | 0 | Timeline | ||
| MARINUS PHARMACEUTICALS INCMARINUS PHARMACEUTICALS INC | 2,516,164 | $3.88M | 2.39% | +1,257,200 | |||
| TRICIDA INCTRICIDA INC | 80,348 | $2.48M | 1.53% | -209,398 | |||
| KINIKSA PHARMACEUTICALS LTDKINIKSA PHARMACEUTICALS LTD | 277,137 | $2.36M | 1.46% | -35,183 | |||
| BELLEROPHON THERAPEUTICS INCBELLEROPHON THERAPEUTICS INC | 2,417,227 | $1.17M | 0.72% | 0 | |||
| RADIUS HEALTH INCRADIUS HEALTH INC | 23,131 | $596K | 0.37% | new | |||
| CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL | 66,667 | $431K | 0.27% | 0 | |||
| YUMANITY THERAPEUTICS INCYUMANITY THERAPEUTICS INC | 221,267 | $187K | 0.12% | 0 | |||
| PREVAIL THERAPEUTICS INCPREVAIL THERAPEUTICS INC | 4,408 | $54K | 0.03% | new |
Sold out in Q3 2019
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| ORCHARD THERAPEUTICS PLCORCHARD THERAPEUTICS PLC | 676,252 | $9.46M | shares |
| KADMON HOLDINGS INCKADMON HOLDINGS INC | 422,141 | $870K | shares |
| GEMPHIRE THERAPEUTICS INCGEMPHIRE THERAPEUTICS INC | 798,066 | $646K | shares |
How Q3 2019 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-19-010838 | base | 2019-11-13 | acceptance time not in the bulk data set |